A Multi-Center, Two-Stage, Open-Label, Prospective, Fellow-Eye Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Travoprost (Primary)
- Indications Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Envisia Therapeutics
- 17 Aug 2017 Planned number of patients changed from 41 to 46.
- 17 Aug 2017 Planned End Date changed from 31 Mar 2018 to 31 Oct 2018.
- 17 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 2 Jan 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History